Based on this understanding, gut-derived serotonin exacerbates hepatic steatosis through direct actions on liver, and gut TPH1–liver 5-HTR2A axis might be a potential drug target for anti-MASLD therapies. The gene discussed is TPH1; the disease is metabolic dysfunction-associated steatotic liver disease.